Citations

Showing 10 of 108104 citations.

Impact of the COVID-19 Pandemic on Patient Fertility Care
DSouza, Karen N. , Orellana, Minerva , Ainsworth, Alessandra J. , Cummings, Gabrielle , Riggan, Kirsten A. , Shenoy, Chandra C. , Allyse, Megan , Allyse, Megan A , Cope, Adela G. , D'Souza, Karen N , Orellana, Minerva A , Riggan, Kirsten A

Mayo Clinic

Journal of Patient Experience | May 6, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23743735221098255 | PMID 35548663 Get It

The effects of the COVID-19 pandemic on the healthcare system have been widespread, with many institutions in the United States pausing elective procedures to redirect resources to critical care. Fertility care and assisted reproductive procedures were classified as elective procedures and similarly paused. We conducted qualitative interviews with patients and/or their partners ( n = 25 female patients; n = 3 male partners) receiving care at a fertility clinic in the Midwest to understand patient appraisal of COVID-19 risk on the resumption of care following a month-long closure of an infertility clinic, and patient agreement with the clinic closure. Interview transcripts were thematically analyzed from a grounded theory approach. Study participants reported an increased sense of urgency due to the delay in fertility procedures. This urgency often superseded concerns of potential COVID-19 infection, motivating patients to continue fertility treatment during a pandemic. In hindsight, some participants did not agree with the clinic's closure and treatment cessation, feeling that these steps negatively interrupted time-sensitive reproductive goals. Patient responses highlight the need for additional resources to support decision-making during times of crisis. Triaging patients based on time-sensitivity of treatment instead of a total shutdown respects patient autonomy for continuing treatment amidst uncertain COVID-19-impact.
Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulation
Sladky, Vladimir , Nejedlý, Petr , Brinkmann, Benjamin H. , Kim, Inyong , Louis, Erik K. St. , Gregg, Nicholas M. , Lundstrom, Brian N. , Crowe, Chelsea M. , Attia, Tal Pal , Crepeau, Daniel, Balzekas, Irena , Wheeler, Lydia , Cook, Mark , Sturges, Beverly K., Leyde, Kent, Miller, Kai J. , Křemen, Václav , Mívalt, Filip , Brinkmann, Benjamin H , St Louis, E K , Gregg, Nicholas M , Lundstrom, Brian Nils , Pal Attia, Tal , Marks, Victoria S , Wheeler, Lydia P, Van Gompel, Jamie J , Kremen, Vaclav , Cook, Mark J , Marks, Victoria S. , Cimbálník, Jan , Janča, Radek , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

Brain Communications | May 6, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcac115 | PMID 35755635 Get It

Abstract Early implantable epilepsy therapy devices provided open-loop electrical stimulation without brain sensing, computing, or an interface for synchronized behavioural inputs from patients. Recent epilepsy stimulation devices provide brain sensing but have not yet developed analytics for accurately tracking and quantifying behaviour and seizures. Here we describe a distributed brain co-processor providing an intuitive bi-directional interface between patient, implanted neural stimulation and sensing device, and local and distributed computing resources. Automated analysis of continuous streaming electrophysiology is synchronized with patient reports using a handheld device and integrated with distributed cloud computing resources for quantifying seizures, interictal epileptiform spikes and patient symptoms during therapeutic electrical brain stimulation. The classification algorithms for interictal epileptiform spikes and seizures were developed and parameterized using long-term ambulatory data from nine humans and eight canines with epilepsy, and then implemented prospectively in out-of-sample testing in two pet canines and four humans with drug-resistant epilepsy living in their natural environments. Accurate seizure diaries are needed as the primary clinical outcome measure of epilepsy therapy and to guide brain-stimulation optimization. The brain co-processor system described here enables tracking interictal epileptiform spikes, seizures and correlation with patient behavioural reports. In the future, correlation of spikes and seizures with behaviour will allow more detailed investigation of the clinical impact of spikes and seizures on patients.
Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial
Stodtmann, Sven , Chen, Mong‐Jen , Siovitz, Lucia , Bereswill, Mareike, Lazar, Andreas, Croft, Nicholas M. , Faubion, William A. , Mostafa, Nael M., Croft, Nicholas , Mostafa, Nael M , Kierkuś, Jarosław

Mayo Clinic

Journal of Crohn's and Colitis | May 6, 2022 | Volume: 16 | Issue: 10 | Pages: 1551-1561

10.1093/ecco-jcc/jjac066 | PMID 35526272 Get It

Abstract Background and Aims The Phase 3 study ENVISION I demonstrated efficacy and safety of adalimumab in paediatric patients with moderate to severe ulcerative colitis. The protocol-specified high-dose adalimumab regimen was numerically more efficacious than the standard-dose regimen. The objective of this work was to bridge a fixed-dosing regimen to the protocol-specified high-induction/high-maintenance, body weight-based dosing regimen studied in ENVISION I, using a pharmacometrics modelling and simulation approach. Methods A stepwise strategy was implemented, including developing an adalimumab paediatric population pharmacokinetic model; using this model to determine a fixed-dosing regimen in paediatric ulcerative colitis patients which achieves similar concentrations to those observed in ENVISION I patients; determining adalimumab exposure-response relationship using population pharmacokinetic/pharmacodynamic model and data from ENVISION I; simulating clinical remission rate in paediatric ulcerative colitis patients using the Markov exposure-response model and the dosing regimen determined to provide similar efficacy to that observed in ENVISION I. Results Both developed population pharmacokinetic and pharmacokinetic/pharmacodynamic models adequately described the observed data. Adalimumab exposure was identified as a significant predictor of clinical remission at Week 8 based on logistic regression [p <0.01]. Simulated efficacy suggested that the fixed-dosing regimen performs similarly to the more efficacious dosing regimen used in ENVISION I, by providing comparable clinical remission per Partial Mayo Score response rates over time. No relationship between adalimumab exposure and adverse events was identified. Conclusions The population pharmacokinetic/pharmacodynamic model supports the appropriateness of the use of the fixed-dosing regimen in the paediatric ulcerative colitis population.
Safety of Percutaneous Femoral Access for Endovascular Aortic Aneurysm Repair Through Previously Surgically Exposed or Repaired Femoral Arteries
Meertens, Max M. , Tenorio, Emanuel R. , Lemmens, Charlotte , Marcondes, Giulianna B. , Lima, Guilherme Baumgardt Barbosa , Schurink, Geert Willem H. , Mendes, Bernardo C. , Oderich, Gustavo S. , Tenorio, Emanuel R , Lima, Guilherme B , Oderich, Gustavo S. , Mees, Barend M.E.

Mayo Clinic

Journal of Endovascular Therapy | May 6, 2022 | Volume: 30 | Issue: 5 | Pages: 730-738

10.1177/15266028221092980 | PMID 35514295 Get It

Objective: Percutaneous femoral artery access is being increasingly used in endovascular aortic repair (EVAR). The technique can be challenging in patients with previously surgically exposed or repaired femoral arteries because of excessive scar tissue. However, a successful percutaneous approach may cause less morbidity than a “re-do” open femoral approach. The aim of this study was to assess the impact of prior open surgical femoral exposure on technical success and clinical outcomes of percutaneous approach. Methods: This study retrospectively reviewed the clinical data of patients who underwent percutaneous EVAR between 2010 and 2020 at 2 major aortic centers. Patients were divided into 2 groups (with or without prior open surgical femoral access) for analysis of clinical outcomes. Only punctures with sheaths ≥12Fr were included for analysis. The access and (pre)closure techniques were similar in both institutions. Primary end points were intraoperative technical success, access-related revision, and access complications. A multivariate analysis was performed to identify determinants of conversion to open approach and femoral access complications in intact and re-do groins. Results: A total of 632 patients underwent percutaneous (complex) EVAR: 98 had prior open surgical femoral access and 534 patients underwent de novo femoral percutaneous access. A total of 1099 femoral artery punctures were performed: 149 in re-do and 950 in intact groins. The extent of endovascular repair included 159 infrarenal, 82 thoracic, 368 fenestrated/branched, and 23 iliac branch devices. No significant differences were seen in technical success (re-do 93.3% vs intact 95.3%, p=0.311), access-related surgical revision (0.7% vs 0.6%, p=0.950), and access complications (2.7% vs 4.0%, p=0.443). For the whole group, significant predictors for access complications in multivariate analyses were main access site (odds ratio [OR] 2.39; 95% confidence interval [CI] 1.07%–5.35%; p=0.033) and increase of the procedure time per hour (OR 1.65; 95% CI 1.34%–2.04%; p<0.001), while increase in sheath-vessel ratio had a protective effect (OR 0.33; 95% CI 0.127%–0.85%; p=0.021). Surgical conversion was predicted by main access site (OR 2.32; 95% CI 1.28%–4.19%; p=0.007) and calcification of 50% to 75% of the circumference of the access vessel (OR 3.29; 95% CI 1.38%–7.86%; p=0.005). Conclusion: Within our population prior open surgical femoral artery exposure or repair had no negative impact on the technical success and clinical outcomes of percutaneous (complex) endovascular aortic aneurysm repair.
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition
Tassorelli, Cristina , Silberstein, Stephen D. , Szperka, Christina L. , Kurth, Tobias , Amin, Faisal Mohammad , Tassorelli, Cristina , Silberstein, Stephan D , Szperka, Christina L , Kurth, Tobias , Diener, Hans-Christoph , Schwedt, Todd J. , Pozo‐Rosich, Patricia , Lipton, Richard B. , Dodick, David W. , Ashina, Messoud , Diener, Hans‐Christoph , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | May 6, 2022 | Volume: 42 | Issue: 11-12 | Pages: 1099-1115

10.1177/03331024221099035 | PMID 35514209 Get It

Clinic-based headache registries collect data for a wide variety of purposes including delineating disease characteristics, longitudinal natural disease courses, headache management approaches, quality of care, treatment safety and effectiveness, factors that predict treatment response, health care resource utilization, clinician adherence to guidelines, and cost-effectiveness. Registry data are valuable for numerous stakeholders, including individuals with headache disorders and their caregivers, healthcare providers, scientists, healthcare systems, regulatory authorities, pharmaceutical companies, employers, and policymakers. This International Headache Society document may serve as guidance for developing clinic-based headache registries. Use of registry data requires a formal research protocol that includes: 1) research aims; 2) methods for data collection, harmonization, analysis, privacy, and protection; 3) methods for human subject protection; and 4) publication and dissemination plans. Depending upon their objectives, headache registries should include validated headache-specific questionnaires, patient reported outcome measures, data elements that are used consistently across studies (i.e., “common data elements”), and medical record data. Amongst other data types, registries may be linked to healthcare and pharmacy claims data, biospecimens, and neuroimaging data. Headache diagnoses should be made according to the International Classification of Headache Disorders diagnostic criteria. The data from well-designed headache registries can provide wide-ranging and novel insights into the characteristics, burden, and treatment of headache disorders and ultimately lead to improvements in the management of patients with headache.
P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes models
Farhadi, Aisan, Nabavi, Seyed Masood, Baharvand, Hossein , Pakdaman, Hossein , Hajizadeh‐Saffar, Ensiyeh , Mousavi, Seyed Ahmad , Hadi, Fatemeh , Zhang, Jin‐San , Tahamtani, Yaser , Shahpasand, Koorosh , Shahpasand, Koorosh , Totonchi, Mehdi , Sinawi, Hamed Al , Li, Quan

Mayo Clinic

European Journal of Neuroscience | May 5, 2022 | Volume: 56 | Issue: 1 | Pages: 3755-3778

10.1111/ejn.15686 | PMID 35513862 Get It

Abstract Diabetes mellitus may cause tau protein hyperphosphorylation and neurodegeneration, but the exact mechanism by which diabetic conditions induce tau pathology remains unclear. Tau protein hyperphosphorylation is considered a major pathological hallmark of neurodegeneration and can be triggered by diabetes. Various tau‐directed kinases, including P38, can be activated upon diabetic stress and induce tau hyperphosphorylation. Despite extensive research efforts, the exact tau specie(s) and kinases driving neurodegeneration in diabetes mellitus have not been clearly elucidated. We herein employed different techniques to determine the exact molecular mechanism of tau pathology triggered by diabetes in in vivo and in vitro models. We showed that diabetes‐related stresses and glucose metabolism deficiency could induce cis P‐tau (an early driver of the tau pathology) accumulation in the midbrain and corpus callosum of the diabetic mice models and cells treated with 2‐deoxy‐D‐glucose, respectively. We found that the active phosphorylated level of P38 was increased in the treated cells and diabetic mice models. We observed that oxidative stress activated P38, which directly and indirectly drove tau pathology in the GABAergic and glutamatergic neurons of the midbrain of the diabetic mice after 96 h, which accumulated in the other neighboring brain areas after 2 months. Notably, P38 inhibition suppressed tau pathogenicity and risk‐taking behaviors in the animal models after 96 h. The data establish P38 as a central mediator of diabetes mellitus‐induced tau pathology. Our findings provide mechanistic insight into the consequences of this metabolic disorder on the nervous system.
Complex cranial surgery and the future of open cerebrovascular training
Graffeo, Christopher S. , Link, Michael J., Lawton, Michael T. , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | May 5, 2022 | Volume: 137 | Issue: 5 | Pages: 1554-1561

10.3171/2022.3.jns212939 | PMID 35535838 Get It

Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate
Singal, Ashwani K. , DiMartini, Andrea F. , Arab, Juan Pablo , Kuo, Yong‐Fang , Shah, Vijay H. , DiMartini, Andrea , Arab, Juan P , Singal, Ashwani K , Leggio, Lorenzo

Mayo Clinic

Alcohol and Alcoholism | May 5, 2022 | Volume: 57 | Issue: 5 | Pages: 576-580

10.1093/alcalc/agac015 | PMID 35544033 Get It

Abstract Aims Readmission is frequent among patients with cirrhosis and is a complex multifactorial process. To examine the association of alcohol use disorder (AUD) and risk of readmission in patients with alcohol-associated cirrhosis. Methods and Results National Readmission Dataset (2016–2017) was used to extract a retrospective cohort of 53,348 patients with primary or secondary discharge diagnosis code of alcohol-associated cirrhosis with their first admission (26,674 patients with vs. propensity matched 26,674 without a primary or secondary discharge diagnosis code of AUD). Readmission within 30-day was lower (43.9 vs. 48%, P &lt; 0.001) among patients identified to have AUD at the time of discharge. In a conditional logistic regression model, a diagnosis of AUD was associated with 15% reduced odds of 30-day readmission, 0.85 (0.83–0.88). Furthermore, the reason for readmission among patients identified vs. not identified to have AUD was less likely to be liver disease complication. The findings remained similar in a matched cohort of patients where the AUD diagnosis at discharge was listed as one of the secondary diagnoses only. Conclusion Although, our study findings suggest that identification of AUD at the time of discharge among patients hospitalized for alcohol-associated cirrhosis reduces the risk of 30-day readmission, unavailable information on patient counseling, referral for mental health specialist and treatment received for AUD limit the causality assessment. Future studies are needed overcoming the inherent limitations of the database to establish the role of identification and treatment of AUD in reducing readmission and liver decompensation in patients with alcohol-associated cirrhosis.
MO421: Chronic Kidney Disease is Associated With Cardiac Downregulation of Vascular Endothelial Growth Factor a (VEGFA) and Development of Diastolic Dysfunction: Epigenetics and Micrornas
Chade, Alejandro , Eirin, Alfonso

Mayo Clinic

Nephrology Dialysis Transplantation | May 5, 2022 | Volume: 37 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfac070.035 Get It

Abstract BACKGROUND AND AIMS Patients with chronic kidney disease (CKD) have a higher risk to develop heart failure with preserved ejection fraction (HFpEF). We showed in a swine model of CKD with diastolic dysfunction and cardiac remodelling that these cardiac features are associated with blunted cardiac mRNA and protein expression of vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine that plays important roles in cardiac vascular development, morphogenesis and contractility. Hence, we aim to identify potential underlying mechanisms of cardiac VEGF downregulation in CKD. METHOD CKD and normal pigs (n = 3 each) were studied for 14 weeks. Cardiac morphology and function (echocardiography) were quantified in vivo and microvascular density (3D micro-CT) ex vivo. Then, cardiac micro-RNA (miRNA) and 5-hydroxymethylcytosine (5-hmC) profiles of VEGFA gene were examined by hydroxymethylated DNA immunoprecipitation and miRNA sequencing (hMeDIP-seq and miRNA-seq, respectively) and validated by qPCR and Western blotting. RESULTS Blunted renal function in CKD pigs associated with left ventricular (LV) hypertrophy, and abnormal LV strain and diastolic dysfunction with pEF (Figure 1A) and reduced subendocardial microvascular density (Figure 1B) compared to normal. miRNA-seq showed that mir-183 was the only miRNA capable of targeting VEGFA and upregulated in CKD hearts (Figure 1C), accompanied by downregulation of VEGFA gene and VEGF protein (Figure 1D), whereas hMeDIP-seq revealed reduced VEGFA 5hmC levels in the hearts of CKD versus normal pigs (Figure 1E). CONCLUSION Our study suggests that miRNA-modulation and cardiac epigenetic changes in VEGF might contribute to cardiac damage and the development of HF in CKD. These observations may assist in developing novel therapies, like miRNA antagonists or epigenetic modulators, to preserve VEGF signalling and protect the heart in patients with CKD.
MO461: A Novel Chronic Kidney Disease to HFpEF Connection: Inflammatory Signaling, Micro-RNAs, and NF-KB
Chade, Alejandro , Mohamed, Tamer , Miller, Jessica M. , Aboulesia, Riham, Ouand, Qinghui, Saadiq, Ishran M. , Abouleisa, Riham R. E. , Tang, Hui Ru , Eirin, Alfonso

Mayo Clinic

Nephrology Dialysis Transplantation | May 5, 2022 | Volume: 37 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfac070.075 Get It

Abstract BACKGROUND AND AIMS Chronic kidney disease (CKD) is an independent risk factor for heart failure with preserved ejection fraction (HFpEF), a progressive condition that affects ˃50% of patients in dialysis. We developed a swine model of CKD-HFpEF and showed that renal inflammatory signaling plays a key role in HFpEF pathophysiology via cardiac activation of nuclear factor-kappa B (NF-kB). However, the mechanisms of CKD-induced cardiac NF-κB activation remain unclear. We hypothesized that micro-RNA (miRNA)-mediated processes contribute to cardiac NF-kB activation in CKD-HFpEF. METHOD Using an in-silico approach (miRWalk3.0 and TargetScan 7.2), we identified all miRNAs capable of targeting the NFKB Inhibitor Alpha (NFKBIA) gene. We then identified those expressed in swine myocardium and measured their levels in normal and CKD pigs by qPCR. In a biomimetic heart culture system that mimics the cardiac CKD-HFpEF microenvironment, pig heart slices were exposed to plasma from normal or CKD pigs, and cardiac kinetics, NF-kB signaling, and miRNA expression levels were investigated in vitro. RESULTS We identified 5 miRNAs expressed in swine hearts capable of targeting NFKBIA, of which only miR-1271–3p showed higher expression in the myocardium of CKD-HFpEF pigs compared to normal pigs. miR-1271–3p upregulation was mirrored in pig heart slices exposed to plasma from CKD pigs, associated with blunted cardiac contraction/relaxation kinetics, downregulation of NFKBIA, and increased protein expression of NF-κB (Figure). CONCLUSION Our data support a novel pathophysiological mechanism for cardiac activation of NF-κB in CKD via post-transcriptional modulation of NFKBIA partly through miR-1271–3p. This miRNA might represent a novel therapeutic target to ameliorate the deleterious effects that renal inflammatory signaling in CKD imposes on the heart and may lead to HFpEF.